Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Clinical Outcomes With Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Castration-sensitive Prostate Cancer (mCSPC) in the Flatiron Health Electronic Health Records (EHR) Database

NCT07086651 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07086651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07086651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Clinical Outcomes With Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Castration-sensitive Prostate Cancer (mCSPC) in the Flatiron Health Electronic Health Records (EHR) Database
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
July 21, 2025
Completion date
October 31, 2025
Enrollment
1,300 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate, metastatic castration sensitive prostate cancer (mcspc), prostate cancer, prostate neoplasms